Seminar Description

In this webinar Dr. Alexander Kel, the CEO and CSO of geneXplain GmbH, will provide a general introduction into epigenomics and will analyze ATAC-seq data of BPTF knockouts in Acute Myeloid Leukemia (AML) (GSE226670) and ChIP-seq and CUT&RUN data of FOXO1 knockouts in diffuse large B-cell lymphoma (DLBCL) (GSE254405) for enriched transcription factor binding sites, composite modules and upstream regulators, via combined promoter and pathway analysis with TRANSFAC master-regulators and Genome Enhancer. 

In this webinar Prof. Dr. Alexander Kel, the CEO and CSO of geneXplain GmbH, will address the in-depth exploration of how CRISPR gene knockouts can be leveraged for TRANSFAC pathway discovery and the identification of cancer master regulators within the TRANSFAC network.

This seminar will highlight the utility of CRISPR synthetic lethality screens in discovering drug targets and understanding disease mechanisms within TRANSFAC pathways. Alexander will showcase a case study where a synthetic lethal CRISPR screen identified a cancer cell-intrinsic role of PD-L1 in regulating vulnerability to ferroptosis in Homo sapiens (GSE268533). Despite the success of PD-1/PD-L1 inhibitors in cancer therapy, only a minority of patients benefit from these treatments. The presented study uses a genome-wide CRISPR screen to explore the intrinsic function of PD-L1 in head and neck squamous cell carcinoma (HNSCC). This seminar will focus on how synthetic lethality screens, combined with the TRANSFAC database, can uncover pathways and regulatory mechanisms that highlight PD-L1’s role in cancer resilience. Additionally, we’ll discuss how these insights can enhance therapeutic strategies by targeting intrinsic PD-L1 functions.